NRXP NRx Pharmaceuticals, Inc.
Price Chart
Executive Summary
NRx Pharmaceuticals announced an underwritten public offering of common stock, with an option for underwriters to purchase an additional 15%. The offering size is undisclosed, and proceeds will be used for working capital and general corporate purposes. This dilutive event comes as a clinical-stage biotech with no approved products, raising capital to fund operations.
Actionable Insight
Monitor the prospectus supplement for exact offering size and pricing. The dilution overhang is likely to pressure the stock near-term. Given the company's pre-revenue status and reliance on capital markets, this offering signals ongoing cash needs without near-term revenue catalysts.
Key Facts
- NRx Pharmaceuticals intends to offer shares of common stock in an underwritten public offering.
- Underwriter has a 30-day option to purchase up to an additional 15% of shares sold.
- BTIG, LLC is lead bookrunner; Lucid Capital Markets is joint bookrunning manager.
- Proceeds will be used for working capital and general corporate purposes.
- Offering is subject to market conditions; size and terms are not yet disclosed.
- Shares offered under an effective shelf registration statement (Form S-3).
Financial Impact
Undisclosed offering size; dilution will depend on final terms. As a clinical-stage biotech with $167M market cap, even a modest offering (e.g., $20-30M) could dilute existing shareholders by 10-20%.
Risk Factors
- Dilution from the offering could be significant relative to current market cap.
- No disclosed use of proceeds beyond working capital suggests no near-term value-creating catalyst.
- Clinical-stage biotech with no approved products; regulatory and commercial risks remain high.
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305567 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 5, 2026
9d ago
|
Press Release
| $4.12 awaiting T+1 | awaiting T+1 | — | $3.84 (−6.80%) |
|
Jun 4, 2026
10d ago
|
Press Release
| $4.05 awaiting T+1 | awaiting T+1 | — | $3.84 (+5.19%) |
|
Jun 3, 2026
11d ago
|
Press Release
| $4.05 $4.05 | · 0.00% | ▲ +0.40% | $3.84 (+5.19%) |
|
Jun 2, 2026
12d ago
|
Press Release
| $4.05 $4.05 | · 0.00% | ▲ +0.41% | $3.84 (+5.19%) |
|
May 18, 2026
27d ago
|
Press Release
| $3.12 $3.03 | ▼ −2.73% | ▼ −2.08% | $3.84 (+23.27%) |
|
May 14, 2026
4w ago
|
Press Release
| $3.21 $3.28 | ▲ +2.18% | ▲ +3.41% | $3.84 (+19.63%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $2.09 $2.13 | ▲ +1.91% | ▼ −0.98% | $3.84 (+83.73%) |
|
Mar 19, 2026
12w ago
|
Press Release
| $1.84 $1.85 | ▲ +0.54% | ▲ +2.29% | $3.84 (+108.70%) |
|
Feb 24, 2026
15w ago
|
DEFA14A
| $1.91 $1.93 | ▲ +1.05% | ▲ +1.59% | $3.84 (+101.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access